IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IDYA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.47B
- EPS (TTM)
- -$4.50
- Dividend yield
- None
- 52-week range
- 25.46 – 42.68
- Day range
- 25.46 – 26.87
- Volume / Avg
- 1.11M / 933.58K
- Beta
- —
- Shares outstanding
- 96.69M
52-week range
IDYA stock today
IDEAYA Biosciences (IDYA) closed at $25.56 on Nov 20, down 2.33% (-$0.61), versus the S&P 500's 3.70% decline. Shares are 40.1% below their 52-week high of $42.68, set on Aug 25, 2026 and 0.4% above the 52-week low of $25.46, near the bottom of the past year's range. IDYA is down 26.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.8%.
IDEAYA Biosciences has posted a net loss over the last twelve months (EPS of -$4.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About IDEAYA Biosciences
Company profileIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Yujiro S. Hata
- Headquarters
- South San Francisco, CA
- Employees
- 145
- IPO year
- 2019
- Website
- ideayabio.com
Financial highlights
Full financialsIn fiscal 2025, IDEAYA Biosciences generated $218.7 million in revenue, up 3024.4% from fiscal 2024. IDEAYA Biosciences reported a net loss of $113.7 million, compared with a loss of $274.5 million a year earlier. Operating margin was -72.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M |
| Growth | +3024.43% | -70.07% | -54.08% | +82.28% | +43.01% |
| Net income | $-113.70M | $-274.48M | $-112.96M | $-58.66M | $-49.76M |
| EPS (diluted) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$50.69+98.32%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-1.22 vs $-1.26
- Surprise
- +3.17%
IDYA news
All IDYA news- IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine CarcinomasPR Newswire
- IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid TumorsPR Newswire
- IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations EventsPR Newswire
- IDEAYA Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Closes Phase 3 OptimUM-010 TrialNasdaqIDYA, BF.A
- IDEAYA Biosciences GAAP EPS of -$1.22 misses by $0.03, revenue of $10.24M beats by $2.66MSeeking Alpha
- IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business UpdatePR Newswire
- Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings EstimatesNasdaqVRTX, IDYA
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR Newswire
IDEAYA Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs IDYA |
| XNCRXencor Inc. | 33.26 | -2.21% | $2.50B | vs IDYA |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs IDYA |
| ZLABZai Lab Limited ADR | 21.03 | -4.06% | $2.63B | vs IDYA |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs IDYA |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs IDYA |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs IDYA |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs IDYA |
Indexes, lists and sector
IDEAYA Biosciences stock FAQ
What is IDEAYA Biosciences's stock price today?
IDYA last traded at $25.56 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.
Who is IDEAYA Biosciences's CEO?
Mr. Yujiro S. Hata is the chief executive officer of IDEAYA Biosciences Inc., which has about 145 employees.
What is the IDYA 52-week high?
The 52-week high for IDYA is $42.68 and the 52-week low is $25.46. The stock is currently 40.1% below its high.